Side-by-side · Research reference
GonadorelinvsHumanin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedHUMAN-REVIEWED7/61 cited
BAnimal-StrongHUMAN-REVIEWED14/52 cited
Gonadorelin
GnRH Analogue · Diagnostic & Therapeutic
IV / SQ · Pulsatile Pump (Therapeutic) · Single Bolus (Diagnostic)
Humanin
Mitochondrial-Derived Peptide · Cytoprotective
SQ · Experimental
01Mechanism of Action
Parameter
Gonadorelin
Humanin
Primary target
GnRH receptors on anterior pituitary gonadotropes
Pathway
GnRH → Pituitary gonadotrope → LH/FSH secretion → Gonadal steroidogenesisSharma 2026
Humanin binds Bax/Bim → inhibits mitochondrial outer membrane permeabilization (MOMP) → blocks cytochrome c release → prevents caspase activation → cell survival
Downstream effect
Pulsatile LH/FSH release stimulates testicular testosterone or ovarian estradiol/progesterone synthesis; initiates folliculogenesis and spermatogenesisRobin 2026Sharma 2026
Suppression of apoptosis, mitochondrial stabilization, reduced oxidative stress, preservation of germ cells and neurons under stressZhu 2022Lue 2021Velentza 2024
Feedback intact?
Yes — pulsatile delivery preserves negative feedback loops; continuous exposure desensitizes receptors
Not applicable — peptide acts as anti-apoptotic signal, not hormonal axis
Origin
Synthetic decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) identical to native hypothalamic GnRH
Encoded by short open reading frame in mitochondrial 16S rRNA gene (MTRNR2). 24-28 amino acids. 13 homologous variants (MTRNR2L1-L13) identified.Zhu 2022Shahzaib 2026
Antibody development
—
Not reported in animal models
02Dosage Protocols
Parameter
Gonadorelin
Humanin
Diagnostic test (pituitary function)
100 mcg IV or SQ bolus
Measure baseline LH/FSH, then 30/60/90 min post-injection. Normal response: LH ≥2× baseline.
—
Therapeutic (hypothalamic hypogonadism)
5–20 mcg IV bolus every 90–120 minutes
Requires portable pulsatile pump. Dose individualized to achieve normal gonadotropin pulsatility.Robin 2026
—
Pulsatile interval
90 minutes (females) · 120 minutes (males)
Mimics physiological GnRH pulse frequency.
—
Route
IV preferred (therapeutic) · SQ acceptable (diagnostic)
—
Duration
Continuous until pregnancy achieved or fertility goals met
3–6 month courses typical for ovulation induction.
8–12 weeks in animal studies
Half-life
2–4 minutes (plasma)
Necessitates frequent pulsatile administration.
—
Alternative protocols
Exogenous gonadotropins (hCG/hMG) often preferred due to convenience vs pump requirement
—
Standard experimental dose (HNG)
—
4 mg/kg IP (rat)
Most common dose in rodent models.
Ex vivo bone culture
—
1 µg/mL
Protective against venetoclax-induced bone growth retardation.
Frequency
—
Daily (IP)
Human data
—
None — no clinical trials reported
Analog (HNG)
—
Gly[14]-humanin — more potent variant
Substitution at position 14 enhances cytoprotective activity.
03Metabolic / Fat Loss Evidence
Parameter
Gonadorelin
Humanin
Fat loss mechanism
None — gonadorelin acts exclusively on reproductive axis
—
Indirect metabolic effects
Restoration of sex hormones may normalize body composition in hypogonadal states
Effect mediated by downstream testosterone/estradiol, not GnRH itself.
—
Direct fat loss evidence
—
None
Mechanism overlap
—
Mitochondrial health may indirectly influence metabolic efficiency, but no quantified effect
04Side Effects & Safety
Parameter
Gonadorelin
Humanin
Injection site reaction
Erythema, irritation (pulsatile pump catheter site)
Not reported in animal studies (IP route)
Headache
Common with bolus administration
—
Nausea / abdominal discomfort
Transient, dose-related
—
Ovarian hyperstimulation syndrome (OHSS)
Risk with ovulation induction protocols; monitor follicular development via ultrasound
—
Multiple gestation
Increased risk with fertility protocols (twins ~10–15%)
—
Anaphylaxis
Rare hypersensitivity reaction
—
Pump malfunction / infection
Mechanical failure or catheter-site infection with long-term IV pump use
—
Receptor desensitization
Continuous (non-pulsatile) exposure paradoxically suppresses gonadotropinsRobin 2026
—
Animal model safety
—
Well-tolerated in rat and mouse studies at 4 mg/kg for 8–12 weeks
Human safety data
—
None — no clinical trials
Theoretical fibrillation risk
—
Induces amyloid-like fibrillation of Bax/BID. Long-term sequelae unknown.
Reproductive safety
—
Protective in POI model (cyclophosphamide-induced), no adverse effects on fertility notedHuang 2025
Absolute Contraindications
Gonadorelin
- ·Pregnancy (except therapeutic infertility protocols)
- ·Hypersensitivity to gonadorelin or excipients
- ·Hormone-dependent tumors (prostate, breast) — risk of tumor stimulation via sex hormone elevation
Humanin
- ·Unknown — no human data
Relative Contraindications
Gonadorelin
- ·Ovarian cysts or PCOS (monitor for OHSS)
- ·Pituitary adenoma or other sellar mass (may worsen with gonadotropin surge)
Humanin
- ·Active malignancy (theoretical risk of anti-apoptotic effect on tumour cells)
05Administration Protocol
Parameter
Gonadorelin
Humanin
1. Diagnostic protocol
Administer 100 mcg IV or SQ bolus. Draw baseline LH/FSH, then at 30, 60, 90 minutes. Normal response: LH ≥2× baseline, FSH modest rise. Blunted response suggests pituitary pathology; exaggerated response may indicate primary hypogonadism.
Intraperitoneal (IP) in animal models. Subcutaneous route untested. No human protocols exist.
2. Therapeutic pump setup (pulsatile)
Requires programmable infusion pump with IV catheter. Set pulse interval to 90 min (females) or 120 min (males). Bolus dose 5–20 mcg per pulse. Pump worn continuously; catheter site rotated every 48–72 hrs to prevent infection.
Synthetic peptide reconstituted in sterile saline or PBS. No commercial formulation available.
3. Reconstitution
Lyophilised gonadorelin reconstituted with sterile saline or provided diluent. Typically 0.8–3.2 mg dissolved in 8 mL for pump reservoir. Solution stable 7–14 days refrigerated.
Daily administration in animal studies. Optimal timing not characterized.
4. Monitoring
For fertility protocols: ultrasound follicular tracking + serial estradiol/LH measurements. Adjust pulse dose to achieve mid-follicular LH 5–10 IU/L. Ovulation confirmed by progesterone rise or ultrasound.
Lyophilised powder: -20 °C. Reconstituted: 4 °C, use within 7 days. Avoid freeze-thaw cycles.
5. Timing
Pulsatile therapy initiated at any point in cycle. Diagnostic test performed in morning (higher baseline LH). For ovulation induction, treatment begins early follicular phase.
No FDA approval, no IND, no clinical trials. Experimental research tool only.
06Stack Synergy
Gonadorelin
+ hCG (Human Chorionic Gonadotropin)
Multi-pathwayIn hypogonadotropic hypogonadism protocols, gonadorelin restores pituitary LH/FSH pulsatility, while exogenous hCG directly stimulates Leydig cells (acting as LH mimetic) to maintain testosterone production. This dual approach ensures both central axis restoration and immediate gonadal steroidogenesis, preventing testicular atrophy during fertility treatment. hCG's longer half-life (24–36 hrs) complements gonadorelin's pulsatile short-acting profile.
- Gonadorelin
- 5–10 mcg IV every 120 min (pulsatile pump)
- hCG
- 1500–2000 IU SQ · 2–3× per week
- Duration
- 12–24 weeks for spermatogenesis induction
- Primary benefit
- Fertility restoration in hypothalamic hypogonadism with maintained testicular function
Humanin
+ MOTS-c
Multi-pathwayBoth are mitochondrial-derived peptides. MOTS-c enhances metabolic efficiency and insulin sensitivity via AMPK activation, while humanin prevents mitochondrial apoptosis. Combined, they address mitochondrial function (MOTS-c) and survival signaling (humanin), supporting cellular resilience under metabolic and oxidative stress.
- Humanin
- 4 mg/kg IP · daily (animal model)
- MOTS-c
- 5 mg/kg IP · daily (animal model)
- Frequency
- Once daily
- Primary benefit
- Mitochondrial health, metabolic efficiency, anti-apoptotic signaling